iiinova — where your digital self keeps evolving

Reposted by Nidia Messias

NKF Nephrology Professionals @nkf-professionals.bsky.social · 16/06/2025

What Causes Kidney Stones? In our latest podcast, a team of health pros debunks myths, shares facts, and offers real-world strategies to stop stones before they start. 🎙️ From diet to hydration to meds—we’ve got it covered. 🔗 Listen now!

bit.ly

Kidney Commute

Tune in for the latest research and perspectives on kidney health from NKF.

011

Reposted by Nidia Messias

kireports.bsky.social @kireports.bsky.social · 02/04/2025

The Prevalence and Characteristics of #IgA Antibodies to β2-spectrin and #CBX3 in IgA Nephropathy #VisualAbstract by @edgarvlermamd.bsky.social www.kireports.org/ar...

041

Reposted by Nidia Messias

Journal of Clinical Investigation @jci.org · 11/03/2025

Does autoimmunity underlie minimal change disease? Tobias B. Huber, Nicola M. Tomas & team report a direct pathogenic role of anti-nephrin autoantibodies in the development of podocytopathy with a minimal change disease phenotype: buff.ly/xTRvnoZ

083

Reposted by Nidia Messias

Arvind (Canchi) Conjeevaram @arvindcanchi.bsky.social · 26/02/2025

Microvascular Inflammation in TX Biopsies - As compared with pts without rejection, the hazard ratio for graft loss was 2.1 among patients with microvascular inflammation without evidence of an antibody-mediated response & 2.7 among patients with ABMR www.nejm.org/doi/full/10.... @nejm.org #nephsky

043

Reposted by Nidia Messias

Sociedad Española de Nefrología @senefrologia.bsky.social · 25/02/2025

🔴Los editores de @ajkd.bsky.social seleccionan el artículo del estudio #GENSEN como investigación relevante para celebrar el #WorldKidneyDay #DíaMundialdelRiñón 👏👏 🔴Se trata de un gran trabajo multicéntrico realizado por SOCIOS S.E.N. ¡GRACIAS! 👇👇 ajkd.org/content/worl...

ajkd.org

American Journal of Kidney Diseases

022

Reposted by Nidia Messias

NEJM.org @nejm.org · 06/02/2025

New in the February 6, 2025, issue of NEJM: Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) nej.md/3UmrOkh Atrasentan in Patients with IgA Nephropathy (ALIGN phase 3 trial) nej.md/3NzvISW Liraglutide for Children with Obesity (SCALE Kids phase 3a trial) nej.md/3MBP1uc #MedSky

Images and descriptions of what's available on NEJM.org this week

1147

Reposted by Nidia Messias

Kajaree @kajareeg.bsky.social · 30/01/2025

🎉 Thrilled to share our commentary in Kidney International Reports ✅Is it time to expand the use of SGLT2 inhibitors in KTRs? ▶️Read on www.kireports.org/article/S246... @theisn.org @kireports.bsky.social @myadla.bsky.social @hswapnil.medsky.social @brianrifkin.bsky.social

21710

Reposted by Nidia Messias

𝐑𝐚𝐥𝐩𝐡 𝐌𝐨𝐡𝐭𝐲 𝐌𝐃 𝐌𝐏𝐇 @rmohty.bsky.social · 30/01/2025

Pretty incredible, very hopeful for a similar story to PLA2r

011

Reposted by Nidia Messias

Cathy Quinlan ☘️ 🇦🇺 🌱 @cathyquinlan.bsky.social · 29/01/2025

🔬 Genetic testing is a game-changer in nephrology, but it’s still not routine practice. This paper lays out a clear framework for when and how to use genetic testing in kidney care. 🧵1/4 www.sciencedirect.com/science/arti...

sciencedirect.com

Navigating Genetic Testing in Nephrology: Options and Decision-Making Strategies

Technological advances such as next-generation sequencing (NGS) have enabled high-throughput assessment of the human genome, supporting the usage of g…

13111

Reposted by Nidia Messias

Joseph Flynn, MD @jostflynnmd.bsky.social · 27/01/2025

Comparative Efficacy of Nonsteroid Immunosuppressive Medications in Childhood Nephrotic Syndrome @aspneph @capneph #medsky #nephsky buff.ly/4aC7NNn

1104

Reposted by Nidia Messias

ASN Publications @asnpublications.bsky.social · 08/01/2025

ASN Publications is on Cloud 9 to announce that we’re now on Bluesky! Follow us @asnpublications.bsky.social for the latest from JASN, CJASN, Kidney360, and Kidney News, and tag us in your publication posts too. @asnkidney.bsky.social @kdjhaveri.bsky.social @rajmehrotra.bsky.social

0219

Reposted by Nidia Messias

American Journal of Kidney Diseases @ajkd.bsky.social · 18/12/2024

Clinicopathologic Characteristics of Crystalglobulin-Induced Nephropathy: A Case Series bit.ly/3VyxrMC #VisualAbstract

074

Reposted by Nidia Messias

American Journal of Kidney Diseases @ajkd.bsky.social · 12/12/2024

New on the #AJKDBlog: Timothy Yau interviews Dr. Anuja Java about Clinical Genetic Testing in Nephrology: Core Curriculum 2024 bit.ly/3VtjcZp (FREE)

0187

Reposted by Nidia Messias

ISNkidneycare @theisn.org · 09/12/2024

𝗜𝗦𝗡 𝗠𝗘𝗠𝗕𝗘𝗥𝗦: Join an expert-led course in Kenya on Glomerulonephritis Management – Free registration and travel grants available ow.ly/W96050UnIkn

The International Society of Nephrology is pleased to deliver the Primer Course in Glomerular Diseases in Nairobi, Kenya from May 16-17, 2025.
We aim to repeat this course annually in different locations to make it accessible to all.
The Primer Course in Glomerular Diseases is designed to provide trainees and early career clinicians with an update on the management of glomerulonephritis, including the diagnosis, histopathology and treatment of a comprehensive range of glomerular diseases.

032

Reposted by Nidia Messias

Jasmine Sethi @jasminenephro.bsky.social · 25/11/2024

💇‍♀️Brazilian hair straightening and Oxalate Nephropathy 😱 www.kidney-international.org/article/S008...

1103

Reposted by Nidia Messias

Simone Sanna-Cherchi 🧬 @genetickidneydoc.bsky.social · 22/11/2024

Great original and commentary work!! As often happens, big answers are hidden just in front of our eyes!! #APOL1 #FSGS #RareDisease #NephSky #MedSky

071

Reposted by Nidia Messias

Alexander Woywodt @pwoywodt.bsky.social · 21/11/2024

I have just done my first prescription for targeted release budesonide (kinpeygo) last week🙏 Want to know the factors that influence response to this drug? Paper on this topic now out in CKJ 📣 academic.oup.com/ckj/advance-...

academic.oup.com

Factors influencing early response of IgA Nephropathy following Targeted-release budesonide (TRB) treatment: preliminary results from a multicenter study

AbstractBackground. Formation of galactose-deficient IgA1 (Gd-IgA1) immunoglobulin is the initial step in the immunological cascade leading to IgA nephropa

0113

Reposted by Nidia Messias

Rachel Lennon @rachellennon.bsky.social · 21/11/2024

Delighted to share our latest paper: "The glomerular circadian clock temporally regulates basement membrane dynamics and the podocyte glucocorticoid response" Expertly led by Rebecca Preston & in collaboration with clock superstar Qing Jun Meng pubmed.ncbi.nlm.nih.gov/39515644/ Key findings 👇👇

24212

Reposted by Nidia Messias

David Koch Jr. Glomerular Kidney Center @cuimcglomcenter.bsky.social · 21/11/2024

The David Koch Jr. Glomerular Kidney Center at Columbia University Irving Medical Center is excited to announce our first Bluesky account! Feel free to follow us and we will follow you back.

021

Reposted by Nidia Messias

Emory University Department of Pathology & Laboratory Medicine @emorypathology.bsky.social · 21/11/2024

🔬EPeP is a free resource w/ interactive cases that make learning fun and easy. Dive into real-life scenarios, get instant feedback + print a certificate when you’re done. It’s all FREE! 🔗 pathology.emory.edu/epep #PathSky #Pathology #PathResidents #MedSky #Path2Path #PathMatch25 #PathMatch2025

1157

Nidia Messias @nidiamessias.bsky.social · 20/11/2024

Leaves are falling but the sky is blue!

020

Nidia Messias @nidiamessias.bsky.social · 19/11/2024

For puzzle lovers and lovers of a puzzling GN!

000

Reposted by Nidia Messias

Sayna Norouzi, MD @saynanorouzi.bsky.social · 13/11/2024

Don’t forget to sign up for the upcoming Rare Kidney Disease Conference (virtual and in-person). 300 registrations so far!! www.eeds.com/portal_live_...

041

Reposted by Nidia Messias

Joel Topf @kidneyboy.bsky.social · 18/11/2024

Welcome to Bluesky AJKD!@ajkd.bsky.social

1163

Reposted by Nidia Messias

American Journal of Kidney Diseases @ajkd.bsky.social · 18/11/2024

Clinicopathologic, Proteomic and Outcome Characteristics of Renal Apolipoprotein C-II Amyloidosis: A Case Series bit.ly/4exkQ2W #VisualAbstract

051

Reposted by Nidia Messias

American Journal of Kidney Diseases @ajkd.bsky.social · 18/11/2024

Highlights from the latest issue of AJKD with plain-language summaries on what inspired each study, the basic approach taken, what was learned, and why it matters: - Extreme Heat and Mortality in Dialysis - Chronic Tonsillitis & IgAN Risk in Japan - Kidney Care in Times of Crises bit.ly/48Av7dl

bit.ly

Highlights from the November 2024 Issue

Editor’s Note: We asked authors of Original Investigations to provide short plain-language summaries that would briefly summarize what inspired their study, the basic approach taken, what was…

051

Reposted by Nidia Messias

Anthony Chang, MD @changucanspare.bsky.social · 18/11/2024

You had me at reduced complement activation Pilot study of SGLT-2 inhibitor empagliflozin shows reduced intrarenal complement activation in patients with diabetes and chronic kidney disease www.kireports.org/article/S246...

kireports.org

DEFINE_ME

1205